Trial Profile
Assessment of the impact of Dapagliflozin, and Empagliflozin on Na+/Li+countertransport (SLC) in erythrocyte membranes of healthy volunteers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Acute heart failure; Cardiovascular disorders; Chronic heart failure; COVID 2019 infections; Decompensated heart failure; Gestational diabetes; Heart failure; Insulin resistance; Kidney disorders; Obesity; Prediabetic state; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 30 Oct 2020 New trial record
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology